As FGFR and PLK1 inhibitors are under active clinical development (Dieci et al, 2013; Gutteridge et al, 2016), our findings provide a new rationale of synergistic combination therapy that is readily translatable for patients with KRAS‐mutant lung cancer. Here, PLK1 is linked to lung carcinoma.